Article Versions Notes

Carter RW, Gerardo CJ, Samuel SP, Kumar S, Kotehal SD, Mukherjee PP, Shirazi FM, Akpunonu PD, Bammigatti C, Bhalla A, et al. The BRAVO Clinical Study Protocol: Oral Varespladib for Inhibition of Secretory Phospholipase A2 in the Treatment of Snakebite Envenoming. Toxins. 2023; 15(1):22. https://doi.org/10.3390/toxins15010022

Carter, Rebecca W., Charles J. Gerardo, Stephen P. Samuel, Surendra Kumar, Suneetha D. Kotehal, Partha P. Mukherjee, Farshad M. Shirazi, Peter D. Akpunonu, Chanaveerappa Bammigatti, Ashish Bhalla, and et al. 2023. "The BRAVO Clinical Study Protocol: Oral Varespladib for Inhibition of Secretory Phospholipase A2 in the Treatment of Snakebite Envenoming" Toxins 15, no. 1: 22. https://doi.org/10.3390/toxins15010022

Carter, R. W., Gerardo, C. J., Samuel, S. P., Kumar, S., Kotehal, S. D., Mukherjee, P. P., Shirazi, F. M., Akpunonu, P. D., Bammigatti, C., Bhalla, A., Manikath, N., Platts-Mills, T. F., & Lewin, M. R., on behalf of the BRAVO Study Group. (2023). The BRAVO Clinical Study Protocol: Oral Varespladib for Inhibition of Secretory Phospholipase A2 in the Treatment of Snakebite Envenoming. Toxins, 15(1), 22. https://doi.org/10.3390/toxins15010022